Pharma’s first AI-driven naming platform

Addison Whitney revolutionizes pharmaceutical naming with Ari^TM

MORRISVILLE, N.C. – [February 5, 2025]

Addison Whitney, powered by Syneos Health, a leader in global brand design, proudly announces the launch of Ari™, the pharmaceutical industry’s first AI-driven naming platform.

Designed to address the growing complexities of regulatory and legal naming requirements,  Ari represents a transformative leap forward in pharmaceutical brand naming.

Ari integrates cutting-edge AI, behavioral insights, and unparalleled naming expertise to overcome the challenge of diminishing regulatory and legal white space.

By leveraging advanced features such as Phonetic and Orthographic Computer Analysis (POCA) and real-time trademark assessments, Ari ensures compliance with rigorous global standards from agencies such as the FDA and EMA while maintaining strategic brand alignment. Importantly, Ari enhances, rather than replaces, human creativity and expertise—empowering our teams to explore more possibilities, uncover new opportunities, and craft names that are both innovative and strategically sound.

“Ari represents a significant milestone in AI-powered healthcare solutions.”

“With over 35 years of experience in brand creation, Addison Whitney has reimagined naming to deliver strategic, innovative solutions that enhance brand performance while addressing critical risks such as regulatory rejection during the approval process and ensuring medication safety once the name reaches the market. Ari positions us at the forefront of Gen AI applications in healthcare marketing, setting a new standard for strategic brand naming.”

Jeanine O’Kane 
President, Syneos Health Communications

Ari works in concert with a dynamic design methodology called “Cleaner, safer, smarter,” shifting from sequential name generation to an integrated, parallel process.

This innovative approach enables the simultaneous evaluation of creative, regulatory, and legal factors, empowering clients with stronger, strategically aligned names that are crafted to withstand the increasing stringency of the regulatory and legal landscape.

Key highlights of Ari:

AI-augmented creativity

Generates well-crafted, on-strategy names at an unprecedented scale.

Regulatory and trademark precision

Incorporates phonetic and orthographic computer analysis, trademark legal screening, and market-specific regulatory insights in real time.

Behavioral insights integration

Provides data-driven naming solutions aligned with audience motivations and global market dynamics.

“Ari operates within a secure, proprietary platform that ensures the confidentiality of our clients’ sensitive information while adapting seamlessly to regional regulatory nuances,”added Joe Daley, President, Addison Whitney.

“Its global capabilities make it an indispensable tool for multinational pharmaceutical companies, providing innovative solutions that deliver ‘trademarks without tradeoffs.”